Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.

ABSTRACT: We previously reported that eribulin mesylate (eribulin), a tubulin-binding drug (TBD), could remodel tumor vasculature (i.e. increase tumor vessels and perfusion) in human breast cancer xenograft models. However, the role of this vascular remodeling in antitumor effects is not fully understood. Here, we investigated the effects of eribulin-induced vascular remodeling on antitumor activities in multiple human cancer xenograft models. Microvessel densities (MVD) were evaluated by immunohistochemistry (CD31 staining), and antitumor effects were examined in 10 human cancer xenograft models. Eribulin significantly increased MVD compared to the controls in six out of 10 models with a correlation between enhanced MVD levels and antitumor effects (R²  = 0.54). Because of increased MVD,

SUBMITTER: Ito K 

PROVIDER: S-EPMC5665763 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature